- |||||||||| Journal: Clinical investigations of compounds targeting metabotropic glutamate receptors. (Pubmed Central) - Sep 14, 2022
Antagonists of mGlu2/3Rs (decoglurant and TS-161) have been studied in depression where TS-161 has advanced into a planned Phase 2 study in treatment-resistant depression...The mGlu4R potentiator, foliglurax, did not meet its primary endpoint in patients with Parkinson's disease. Ongoing efforts to develop mGluR-targeted compounds continue to promise these glutamate modulators as medicines for psychiatric and neurological disorders.
- |||||||||| MP-101 / Eli Lilly, Mediti
Trial termination: A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression (clinicaltrials.gov) - Feb 26, 2020
P2, N=84, Terminated,
Ongoing efforts to develop mGluR-targeted compounds continue to promise these glutamate modulators as medicines for psychiatric and neurological disorders. Active, not recruiting --> Terminated; Statistical futility; totality of evidence suggests study unlikely to meet endpoint
- |||||||||| MP-101 / Eli Lilly, Mediti
Enrollment closed, Trial completion date, Trial primary completion date: A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression (clinicaltrials.gov) - Feb 18, 2020
P2, N=84, Active, not recruiting,
Active, not recruiting --> Terminated; Statistical futility; totality of evidence suggests study unlikely to meet endpoint Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Feb 2020 | Trial primary completion date: Aug 2020 --> Feb 2020
- |||||||||| MP-101 / Eli Lilly, Mediti
Trial completion date, Trial primary completion date: A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression (clinicaltrials.gov) - May 31, 2019
P2, N=100, Recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Aug 2020 --> Feb 2020 | Trial primary completion date: Aug 2020 --> Feb 2020 Trial completion date: Jan 2021 --> Aug 2020 | Trial primary completion date: Jan 2021 --> Aug 2020
- |||||||||| MP-101 / Eli Lilly, Mediti
Enrollment change, Trial completion date, Trial primary completion date: A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression (clinicaltrials.gov) - Mar 27, 2018
P2, N=100, Recruiting,
Trial completion date: Jan 2021 --> Aug 2020 | Trial primary completion date: Jan 2021 --> Aug 2020 N=200 --> 100 | Trial completion date: Nov 2018 --> Jan 2021 | Trial primary completion date: Oct 2018 --> Jan 2021
|
